At the news
? BULLISHIMPACT 7/10 8-K filed Aug 3, 2026 at 07:07 ET
Ocular Therapeutix reported Q2 2026 revenue of $13.5M (flat YoY) and a net loss of $(0.35) per share, which is a narrower loss than the $(0.39) in Q2 2025. The key catalyst is the confirmed FDA-aligned path to submit the AXPAXLI NDA for wet AMD in Q4 2026, with a pre-NDA meeting scheduled for Q3 2026. The stock will move on the regulatory clarity and the potential for a 2027 launch, not on the pre-revenue financials.
- AXPAXLI NDA submission for wet AMD on track for Q4 2026 following positive FDA Type C meeting.
- Pre-NDA meeting with FDA scheduled for Q3 2026; NDA to follow 505(b)(2) pathway, potentially accelerating review by up to 60 days.
- Total net revenue was $13.5M for Q2 2026, flat compared to Q2 2025.
- Net loss for Q2 2026 was $(78.8)M, or $(0.35) per share, vs. $(67.8)M, or $(0.39) per share in Q2 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access